Precision oncology is reshaping cancer treatment by shifting the medical focus from broad organ-based classifications to the specific biological characteristics of individual tumors. According to Diego Kaen, former president of the Argentine Association of Clinical Oncology and director of clinical research at the Rioja Integral Oncology Center, targeted therapies and advanced biomarker testing now allow physicians to match patients with precise medications from the onset of diagnosis.
The Shift Toward Precision Oncology and Biomarkers
Traditional cancer treatment often relied on generalized categorizations, treating patients with identical diagnoses using the same standardized medications regardless of individual variations. Kaen explains that modern oncology recognizes tumors as biologically distinct entities even when they originate in the same organ, such as the lungs. Oncologists identify these specific differences using biomarkers, which act as distinct molecular indicators that reveal which targeted drugs will prove effective against a specific tumor.
This molecular approach relies on laboratory techniques including polymerase chain reaction (PCR), next-generation sequencing (NGS), and immunohistochemistry. In specialized settings, such as cases of breast cancer, biomarker analysis is routinely performed alongside the initial biopsy so treatment teams know the required drug regimen immediately upon a patient’s arrival.
Liquid Biopsies and Dynamic Tumor Monitoring
Detecting tumor characteristics no longer depends exclusively on invasive surgical procedures to extract physical tissue samples. Liquid biopsies allow clinicians to analyze tumor-derived DNA released directly into the bloodstream through a standard conventional blood draw.
Kaen notes that liquid biopsies achieve a specificity close to 100 percent when compared with traditional tissue biopsies. Beyond diagnostic convenience, blood-based testing provides a dynamic profile of the disease rather than a static snapshot. Clinicians can measure circulating tumor DNA following surgical resections to detect residual disease early, identifying potential recurrences well before they appear on standard computerized tomography (CT) scans.
Survival Rates and Economic Impacts of Targeted Drugs
The integration of precision medicine has substantially improved survival metrics for advanced malignancies. Kaen points out that five or six years ago, a patient diagnosed with stage 4 lung cancer faced an average survival time of approximately six months. Today, when the ALK biomarker is detected, more than 55 percent of such patients live longer than five years while taking targeted pills that avoid the severe side effects associated with traditional chemotherapy.
Countries that implement national precision medicine frameworks, such as France and Spain, report significant cost savings within their healthcare systems. By avoiding ineffective treatments and unnecessary hospitalizations caused by drug toxicity, targeted testing optimizes resource allocation.
Barriers to Universal Access and Funding
Despite clinical advancements, substantial disparities persist in how patients access biomarker testing. While private health prepaid plans generally cover these diagnostic procedures, public hospitals often require complex administrative approvals, particularly for advanced techniques required in lung cancer diagnostics.
Kaen emphasizes that geographic inequality remains a primary obstacle in Argentina. Because biological materials and blood samples can easily travel at ambient temperature from any province to analytical hubs in Buenos Aires, establishing a unified national plan for precision medicine would make advanced diagnostics universally accessible across both public and private sectors.
Prevention and Lifestyle Factors
Alongside therapeutic innovations, medical experts stress that lifestyle interventions remain critical for curbing the rising incidence of cancer, particularly among younger populations experiencing higher rates of colon, lung, and breast malignancies. Kaen highlights that adopting healthy habits can prevent up to 40 percent of cancer cases.
Effective preventive measures include maintaining a balanced diet rich in fruits and vegetables, engaging in regular physical activity, avoiding tobacco use, minimizing alcohol consumption, protecting skin from harmful solar radiation, and completing vaccinations against hepatitis B and the human papillomavirus (HPV). According to Kaen, maintaining a healthy lifestyle remains more effective than any medical treatment.
Worth a look